Iraq's Kurdistan region sticks with AstraZeneca vaccine, reports no issues
Kurdish authorities say they will continue administering the vaccine following the European Union's conclusion that blood clots should be listed among "rare side effects" of the British-Swedish vaccine.
The Kurdistan Regional Government in Iraq will continue using the AstraZeneca vaccine against COVID-19 after the European Union concluded there is a small chance it could cause blood clots. The British-Swedish vaccine is being deployed in several Middle Eastern countries while some European and African states are restricting its use.
A KRG Health Ministry spokesperson said that there have been no major issues with the AstraZeneca vaccine in the semiautonomous Kurdistan Region and that its administration will continue.
